Modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy

Active Publication Date: 2017-05-25
UNIV DI FERRARA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about a type of RNA molecule called U1snRNA, which can selectively target and act on specific parts of a gene called exons. These exons are more unique and different from the parts that connect them called introns. Surprisingly, the U1snRNA molecules can still induce the inclusion of exons even when there are mutations in the gene. This can help researchers better understand the function of these genes and potentially develop new treatments for genetic diseases.

Problems solved by technology

As a consequence of CFTR modification, the transfer of salts through cell membranes is compromised, mainly causing a production of secretions that could be defined as “dehydrated”: a sweat very rich in sodium and chlorine and a dense and viscous mucus that tends to obstruct the ducts, compromising the function of various organs and systems.
To date, no treatment for this disease, which generally leads to death at an age that depends on the seriousness of the case history, has yet been identified.
However, expression of SMN2 is impaired by a synonymous mutation in the exon which results in an aberrant maturation of the messenger RNA with consequent skipping of exon 7 and inactivation of the gene itself.
However, in neurons, this amount is not sufficient to support a physiological activity, leading to the pathological condition.
However, this method presents a certain degree of non-specificity of action of the therapeutic snRNA molecule towards the target gene, due to the relative conservation of the 5′ss sites and consequent risk of interfering with the maturation of transcripts generated from other functional wild-type genes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
  • Modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy
  • Modified human u1snrna molecule, a gene encoding for the modified human u1snrna molecule, an expression vector including the gene, and the use thereof in gene therapy of familial dysautonomia and spinal muscular atrophy

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of the Modified U1 snRNAs

[0064]The modified U1 snRNAs were generated by the following procedure: the plasmid containing the sequence of the wild-type U1-snRNA gene, that is the non-modified U1-snRNA, was digested with the BglII and Bcll restriction enzymes. The sequence comprised between these two restriction sites was replaced with a double-stranded oligonucleotide comprising the binding sequence. The direct and reverse sequences of each oligonucleotide are described in Table 1 below and the resulting modified U1-snRNAs are named after the employed oligonucleotides.

[0065]Furthermore, FIG. 2 shows a schematic representation of the U1 snRNA gene elements. The cloning strategy by which the different modified U1 snRNAs were prepared is indicated. FIG. 2 shows the U1snRNA gene with the promoter elements DSE and PSE, the region encoding for U1 snRNA (in the middle), and the 3′ processing box, inserted in a plasmid vector (pGEM). The transcription start site is indicated by an arrow. Th...

example 2

ion of the Minigenes into Cultured Cells and Analysis of the Splicing Products

[0066]The containing-vectors were inserted into the cells by transient transfection with Lipofectamine (liposomes). Following extraction of total cellular RNA with Trizol, the RNA was analyzed by RT-PCR with specific primers.

[0067]The reaction occurs in two steps: the RNA inverse transcription into a cDNA strand by a reverse transcriptase using random primers as templates, and amplification of the obtained cDNA by a DNA polymerase.

[0068]The PCR reaction was carried out in a final volume of 25 μl of a mixture containing:[0069]5 μl of AMV / Tfl 5× buffer suitable for the correct functioning of both the enzymes mentioned above;[0070]1 μl of 10 mM dNTPs mix;[0071]50 pmol of forward primer and 50 pmol of reverse primer;[0072]2 μl 25 mM MgSO4;[0073]2 μl of cell-extracted RNA;[0074]1 μl of AMV-RT (0.1 μ / μl), 1 μl of Tfl DNA polymerase;[0075]ultra pure H2O q.s.

[0076]The reverse transcription step was performed at 45...

example 3

tations Near the Donor Site and Mutations in the Poly-Pyrimidine Sequence Upstream of the Exon 5 Acceptor Site of the Coagulation Factor IX Associated with Hemophilia B

[0078]In the factor IX gene (F9), the exonic mutations at position −2 within the donor site, as well as the mutations at positions −8 and −9 within the acceptor site of exon 5, are associated with hemophilia B. It is interesting to note that the mutations at position −2 in the exon are synonymous and do not modify the coding sequence but induce exon skipping and therefore they are classifiable as splicing mutations. The mutations at positions −8 and -9 within the acceptor site also induce skipping of exon 5.

[0079]Table 2 shows the mutations under discussion which were identified in patients affected by hemophilia B (Hemophilia B International database). Nucleotides belonging to exon 5 are shown in capital letters, whereas those belonging to the intron are in lower case. Each position, shown at the bottom of the figure...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Compositionaaaaaaaaaa
Therapeuticaaaaaaaaaa
Login to view more

Abstract

The invention provides a modified human U1snRNA molecule, capable of correcting the skipping of an exon caused by a mutation localized in the sequence comprised between 50 base pairs upstream and 20 base pairs downstream of an exon, wherein a portion of a single-stranded nucleotide sequence of the 5′ region of the wild-type human U1snRNA is replaced by a single-stranded binding nucleotide sequence, wherein the binding nucleotide sequence is selected from the group consisting of: uggcgcuua, aauggcgcu, aguacaauggcgc (SEQ ID NO: 87), gcaaacaguacaau (SEQ ID NO: 88), ucgcaaacaguaca (SEQ ID NO: 89), gcaaacagu, cuagucgcaaac (SEQ ID NO: 90), uacaaaaguaagauuca (SEQ ID NO: 83), aaaccauaaaguuuuacaa (SEQ ID NO: 84) and caaaccauaaaguuuua (SEQ ID NO: 96).

Description

FIELD OF THE INVENTION[0001]The present invention concerns modified human snRNA molecules (hereinafter designated as Exon Specific U1—ExSpeU1), which are suitable to be used in gene therapy methods. In particular, the invention relates to snRNA molecules capable of correcting aberrant splicing processes caused by genetic mutations and related to human diseases with different case histories, which are often very serious.BACKGROUND OF THE INVENTION[0002]Many human genetic diseases (about 15%) are caused by genetic mutations that, by interfering with the correct messenger RNA intracellular maturation, compromise the accurate subsequent protein biosynthesis and induce synthesis of non-functional proteins. Mostly, the point mutations accountable for splicing defects concern gene sequences that are critical for the recognition of the primary transcript by the machinery appointed for processing the same. The donor and acceptor sites located at the exon-intron boundaries, as well as gene-sp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00C12N15/86
CPCA61K48/0066C12N2750/14143C12N15/86C12N2320/33C12N15/85C12N15/111C12N2330/51A61K48/005C12N2830/00
Inventor PAGANI, FRANCOPINOTTI, MIRKO
Owner UNIV DI FERRARA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap